12:00 AM
 | 
Dec 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GSK2256098: Phase I data

An open-label, international Phase I trial in 29 patients with recurrent mesothelioma showed that twice-daily oral GSK2256098 produced 14 cases of stable disease. Median progression-free survival (PFS) was 17.7 weeks. In patients with neurofibromin 2 (...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >